2018 ; Vol.28-10: 1645~1653
|Author||Eun-Joo Kim, Min-jae Kang, Yong Bae Seo, Soo-Wan Nam, Gun-Do Kim|
|Place of duty||Department of Microbiology, College of Natural Sciences, Pukyong National University, Busan 48513, Republic of Korea|
|Title||Acer okamotoanum Nakai Leaf Extract Inhibits Adipogenesis Via Suppressing Expression of PPAR γ and C/EBP α in 3T3-L1 Cells|
J. Microbiol. Biotechnol.2018 ;
|Abstract||The genus Acer contains several species with various bioactivities including antioxidant,
antitumor and anti-inflammatory properties. However, Acer okamotoanum Nakai, one species
within this genus has not been fully studied yet. Therefore, in this study, we investigated the
anti-adipogenic activities of leaf extract from A. okamotoanum Nakai (LEAO) on 3T3-L1
preadipocytes. Adipogenesis is one of the cell differentiation processes, which converts
preadipocytes into mature adipocytes. Nowadays, inhibition of adipogenesis is considered as
an effective strategy in the field of anti-obesity research. In this study, we observed that LEAO
decreased the accumulation of lipid droplets during adipogenesis and down-regulated the
expression of key adipogenic transcription factors such as peroxisome proliferator-activated
receptor γ (PPAR γ) and CCAAT/enhancer binding protein α (C/EBP α). In addition, LEAO
inactivated PI3K/Akt signaling and its downstream factors that promote adipogenesis by
inducing the expression of PPAR γ. LEAO also activated β-catenin signaling, which prevents
the adipogenic program by suppressing the expression of PPAR γ. Therefore, we found that
treatment with LEAO is effective for attenuating adipogenesis in 3T3-L1 cells. Consequently,
these findings suggest that LEAO has the potential to be used as a therapeutic agent for
|Key_word||Acer okamotoanum, adipogenesis, anti-obesity, 3T3-L1 adipocytes|
Pi-Sunyer FX. 2002. The obesity epidemic: pathophysiology and consequences of obesity. Obesity 10: 97S-104S.
Lawrence VJ, Kopelman PG. 2004. Medical consequences of obesity. Clin. Dermatol. 22: 296-302.
Marti A, Moreno-Aliaga M, Hebebrand J, Martinez J. 2004. Genes, lifestyles and obesity. Int. J. Obes. 28: S29-S36.
Spiegelman BM, Flier JS. 1996. Adipogenesis and obesity:rounding out the big picture. Cell 87: 377-389.
Ali AT, Hochfeld WE, Myburgh R, Pepper MS. 2013. Adipocyte and adipogenesis. Eur. J. Cell Biol. 92: 229-236.
Farmer SR. 2006. Transcriptional control of adipocyte formation. Cell Metabolism. 4: 263-273.
Rosen ED, MacDougald OA. 2006. Adipocyte differentiation from the inside out. Nature Reviews. Mol. Cell Biol. 7: 885-896.
Rosen ED, Sarraf P, Troy AE, Bradwin G, Moore K, Milstone DS, et al. 1999. PPAR γ is required for the differentiation of adipose tissue in vivo and in vitro. Mol. Cell 4: 611-617.
Saltiel AR, Kahn CR. 2001. Insulin signalling and the regulation of glucose and lipid metabolism. Nature 414: 799806.
Laplante M, Sabatini DM. 2012. mTOR signaling in growth control and disease. Cell 149: 274-293.
Christodoulides C, Lagathu C, Sethi JK, Vidal-Puig A. 2009. Adipogenesis and WNT signalling. Trends Endocrinol. Metab. 20: 16-24.
Bi W, G ao Y , S hen J, H e C, L iu H , Peng Y , et al. 2016. Traditional uses, phytochemistry, and pharmacology of the genus Acer (maple): a review. J. Ethnopharmacol. 189: 31-60.
Jin L, Han JG, Ha JH, Jeong HS, Kwon MC, Jeong MH, et al. 2008. Comparison of antioxidant and glutathione S-transferase activities of extracts from Acer mono and A. okamotoanum. Korean J. Med. Crop Sci. 16: 427-433.
Yang H, Hwang I, Koo TH, Ahn HJ, Kim S, Park MJ, et al. 2012. Beneficial effects of Acer okamotoanum sap on L-NAMEinduced hypertension-like symptoms in a rat model. Mol. Med. Rep. 5: 427-431.
Yoo Y, Jung E, Kang H, Choi I, Choi K, Jeung E. 2011. The sap of Acer okamotoanum decreases serum alcohol levels after acute ethanol ingestion in rats. Int. J. Mol. Med. 28: 489-495.
Rayalam S, Della-Fera MA, Baile CA. 2008. Phytochemicals and regulation of the adipocyte life cycle. J. Nutr. Biochem. 19: 717-726.
Yun JW. 2010. Possible anti-obesity therapeutics from nature–a review. Phytochemistry 71: 1625-1641.
Feng S, Reuss L, Wang Y. 2016. Potential of natural products in the inhibition of adipogenesis through regulation of PPAR γ expression and/or its transcriptional activity. Molecules 21: 1278.
Farmer S. 2005. Regulation of PPAR [gamma] activity during adipogenesis. Int. J. Obes. 29: S13-S16.
Rosen E D, H su C H, W ang X, S akai S , Freeman MW, Gonzalez FJ, et al. 2002. C/EBPalpha induces adipogenesis through PPARgamma: a unified pathway. Genes Dev. 16: 22-26.
Eberlé D, Hegarty B, Bossard P, Ferré P, Foufelle F. 2004. SREBP transcription factors: master regulators of lipid homeostasis. Biochimie 86: 839-848.
Kim JB, Spiegelman BM. 1996. ADD1/SREBP1 promotes adipocyte differentiation and gene expression linked to fatty acid metabolism. Genes Dev. 10: 1096-1107.
Chirala S S , Wakil SJ. 2004. S tructure and function of animal fatty acid synthase. Lipids 39: 1045-1053.
Fu Y, Luo N, Klein RL, Garvey WT. 2005. Adiponectin promotes adipocyte differentiation, insulin sensitivity, and lipid accumulation. J. Lipid Res. 46: 1369-1379.
Whitehead JP, Clark S F, Ursø B, James DE. 2 000. S ignalling through the insulin receptor. Curr. Opin. Cell Biol. 12: 222-228.
Khan A, Pessin J. 2002. Insulin regulation of glucose uptake:a complex interplay of intracellular signalling pathways. Diabetologia 45: 1475-1483.
Sasaki T, Takasuga S, Sasaki J, Kofuji S, Eguchi S, Yamazaki M, et al. 2009. Mammalian phosphoinositide kinases and phosphatases. Prog. Lipid Res. 48: 307-343.
Zhang HH, H uang J , Düvel K, Boback B, W u S , S quillace RM, et al. 2009. Insulin stimulates adipogenesis through the Akt-TSC2-mTORC1 pathway. PLoS One 4: e6189.
Kim JE, Chen J. 2004. Regulation of peroxisome proliferatoractivated receptor-gamma activity by mammalian target of rapamycin and amino acids in adipogenesis. Diabetes 53:2748-2756.
Laplante M, Sabatini DM. 2009. An emerging role of mTOR in lipid biosynthesis. Curr. Biol. 19: R1046-R1052.
Fox HL, Kimball SR, Jefferson LS, Lynch CJ. 1998. Amino acids stimulate phosphorylation of p70S6k and organization of rat adipocytes into multicellular clusters. Am. J. Physiol. 274: C206-C213.
Wu D, Pan W. 2010. GSK3: a multifaceted kinase in Wnt signaling. Trends Biochem. Sci. 35: 161-168.
Taurin S, Sandbo N, Qin Y, Browning D, Dulin NO. 2006. Phosphorylation of beta-catenin by cyclic AMP-dependent protein kinase. J. Biol. Chem. 281: 9971-9976.
Grimes CA, Jope RS. 2001. The multifaceted roles of glycogen synthase kinase 3β in cellular signaling. Prog. Neurobiol. 65:391-426.
Ding VW, Chen RH, McCormick F. 2000. Differential regulation of glycogen synthase kinase 3beta by insulin and Wnt signaling. J. Biol. Chem. 275: 32475-32481.
Fang D, Hawke D, Zheng Y, Xia Y, Meisenhelder J, Nika H, et al. 2007. Phosphorylation of beta-catenin by AKT promotes beta-catenin transcriptional activity. J. Biol. Chem. 282: 1122111229.
Liu J, Farmer SR. 2004. Regulating the balance between peroxisome proliferator-activated receptor gamma and betacatenin signaling during adipogenesis. A glycogen synthase kinase 3beta phosphorylation-defective mutant of betacatenin inhibits expression of a subset of adipogenic genes. J. Biol. Chem. 279: 45020-45027.